OakChart

Arcus Biosciences Inc

RCUSHealthcare·Biotechnology·USA·Mid·NYSE·Nov 11 • 1:28 PM ET

18.69+0.02 (0.13%)
2026-11-11 19:28 CET
Market cap
2,688.31 USD m
Revenue, TTM
100.00 USD m
Net income, TTM
-453.00 USD m
Free cash flow, TTM
-466.00 USD m
EPS diluted, TTM
-3.64
P/E
-
Compare

Price

RCUS against its 20, 50 and 200-day averages
2050200beatmiss
20.0025.0030.004.2M8.4MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26RCUSclose 18.6920-day 19.3650-day 23.11200-day 24.5118.6952w high52w low

41.1% under the 52-week high of 31.74 on 30 Jun 2026. 52-week low 17.43 on 22 Oct 2026. Last 15 sessions, 12.6% high to low

Profile

RCUS
52-week range, 9% of the way up
17.4331.74

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology, and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

IndexRUT
Employees601
IPOMar 15, 2018
Beta1.08
ATR, 14d1.25
Rel volume0.23
Short float13.63%
Insider own32.85%
Inst own60.85%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap2.69B
Enterprise Value2.18B
Income-453.00M
Sales100.00M
Book/sh2.81
Cash/sh4.38
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees601
IPOMar 15, 2018

Ratios

P/E-
Forward P/E-
PEG-
P/S26.92
P/B6.66
P/C4.27
P/FCF-
EV/EBITDA-
EV/Sales21.78
Quick Ratio3.34
Current Ratio3.34
Debt/Eq0.32
LT Debt/Eq0.28
Option/ShortYes / Yes

Earnings

EPS (ttm)-3.64
EPS next Y-3.26
EPS next Q-0.86
EPS this Y-9.95%
EPS next Y9.79%
EPS next 5Y3.32%
EPS past 3/5Y3.94% -7.95%
Sales past 3/5Y30.16% 26.08%
EPS Y/Y TTM-6.14%
Sales Y/Y TTM-58.33%
EPS Q/Q20.74%
Sales Q/Q-65.38%
EarningsNov 04 AMC
EPS/Sales Surpr.-12.26% 18.72%

Ownership

Insider Own32.85%
Insider Trans-0.24%
Inst Own60.85%
Inst Trans2.23%
ROA-50.56%
ROE-114.11%
ROIC-98.48%
Gross Margin91.00%
Oper. Margin-475.00%
Profit Margin-453.00%
SMA20-3.46%
SMA50-19.12%
SMA200-23.73%
Trades-

Technical

Shs Outstand127.60M
Shs Float96.69M
Short Float13.63%
Short Ratio7.21
Short Interest13.18M
52W High31.74 -41.10%
52W Low17.43 7.25%
Volatility6.80% 7.68%
ATR (14)1.25
RSI (14)40.06
Beta1.08
Rel Volume0.23
Avg Volume1.83M
Volume262,296

Performance

Perf Week-3.19%
Perf Month-16.95%
Perf Quarter-35.23%
Perf Half Y-25.23%
Perf YTD-21.55%
Perf Year-7.87%
Perf 3Y38.06%
Perf 5Y-50.07%
Perf 10Y-
Recom1.27
Target Price41.00
Prev Close18.67
Price18.69
Change %0.13%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 16, 2026InitiatedWWilliam BlairOutperform
Oct 14, 2026InitiatedJJP MorganOverweight$41+119.3%
Sep 16, 2026InitiatedTTD CowenBuy
May 18, 2026ResumedTTruistBuy$35+87.2%
Feb 12, 2026DowngradeWWells FargoOverweight → Equal Weight$23+23.0%
Jan 13, 2026UpgradeGGoldmanNeutral → Buy$28+49.8%
Jan 08, 2026DowngradeMMorgan StanleyOverweight → Equal-Weight$20+7.0%
Feb 26, 2025UpgradeHH.C. WainwrightNeutral → Buy$18 → $24+28.4%
Oct 21, 2024InitiatedHH.C. WainwrightNeutral$20+7.0%
Oct 08, 2024InitiatedWWells FargoOverweight$29+55.1%

Peers

Mkt cap
TickerCompanyMkt cap
EXELExelixis Inc17.16B
XNCRXencor Inc3.03B
IDYAIdeaya Biosciences Inc3.13B
SMMTSummit Therapeutics Inc13.50B
MRKMerck & Co Inc361.33B
CBIOCrescent Biopharma Inc524.84M
RVMDRevolution Medicines Inc39.41B
IOVAIovance Biotherapeutics Inc3.75B
AGENAgenus Inc328.49M
GILDGilead Sciences Inc210.96B

Insider trading

latest 14 of 56
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Azoy AlexanderChief Accounting OfficerAug 21 '26Option Exercise15.442,82743,64942,408Aug 24 05:52 PM
Azoy AlexanderChief Accounting OfficerAug 21 '26Sale30.002,82784,81039,581Aug 24 05:52 PM
ALEXANDER AZOYOfficerAug 21 '26Proposed Sale29.522,82783,453Aug 21 04:36 PM
Jaen Juan C.PresidentJul 09 '26Sale30.0548,5021,457,631842,307Jul 13 05:36 PM
Jaen Juan C.PresidentJul 10 '26Sale28.6220,067574,288822,240Jul 13 05:36 PM
Juan JaenOfficerJul 09 '26Proposed Sale29.9625,000749,000Jul 09 06:31 PM
Juan JaenOfficerJun 24 '26Proposed Sale28.8050,0001,440,000Jun 24 06:17 PM
Jaen Juan C.PresidentJun 23 '26Sale27.7315,764437,100897,240Jun 24 05:41 PM
Jaen Juan C.PresidentJun 22 '26Sale27.039,236249,661913,004Jun 24 05:41 PM
Jaen Juan C.PresidentJun 24 '26Sale29.666,431190,740890,809Jun 24 05:41 PM
Juan JaenOfficerJun 22 '26Proposed Sale27.2325,000680,750Jun 22 06:31 PM
Tang Carolyn C.General CounselJun 11 '26Option Exercise2.5734,09087,748184,607Jun 12 04:28 PM
Azoy AlexanderChief Accounting OfficerJun 01 '26Sale25.772,56266,02439,581Jun 01 07:23 PM
ALEXANDER AZOYOfficerJun 01 '26Proposed Sale25.342,56264,921Jun 01 04:26 PM

Held by

AUM
TickerCompanyAUM
IJRiShares Core S&P Small-Cap ETFAUM: 106.27B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
SPSMState Street SPDR Portfolio S&P 600TM Small Cap ETFAUM: 16.06B
XSMOInvesco S&P SmallCap Momentum ETFAUM: 2.74B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-1.000-0.891-1.0009.007.5812
2026Q22026-08-05-0.720-0.891-0.72241.0021.989
2026Q12026-05-05-1.020-0.880-1.02117.0029.488
2025Q42026-02-25-0.890-1.106-0.89533.0035.718
2025Q32025-10-28-1.270-1.310-1.26826.0021.0010
2025Q22025-08-060.000-1.1260.00016033.199
2025Q12025-05-06-1.140-1.031-1.13828.0038.6110
2024Q42025-02-25-1.030-1.249-1.02536.0029.3311
2024Q32024-11-06-1.000-1.056-1.00748.0038.9511
2024Q22024-08-08-1.020-1.115-1.02139.0026.248
2024Q12024-05-08-0.050-1.010-0.04614528.779
2023Q42024-02-21-1.080-1.025-1.08031.0028.3011
2023Q32023-11-07-0.940-1.129-0.95232.0027.2811
2023Q22023-08-07-1.040-1.098-1.02529.0031.8111
2023Q12023-05-09-1.090-1.164-1.09625.0025.6811
2022Q42023-02-28-0.930-1.139-0.92934.0023.729

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-1.930-2.004-1.93315.006.46
2020FY-2.240-2.179-2.24377.5275.97
2021FY0.710-4.3480.714382.8840.33
2022FY-3.710-3.881-3.708112102.64
2023FY-4.150-4.003-4.149117113.67
2024FY-3.140-3.411-3.141258261.59
2025FY-3.290-3.554-3.290247246.54
2026FY--3.618--72.40
2027FY--3.263--51.49
2028FY--2.973--78.48
2029FY--1.556--353.76
2030FY-1.071--851.44

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0512155.110.0012.50
2026Q4S2026-11-0412035.490.0012.50
2026Q4S2026-10-2512035.490.0012.50
2026Q4S2026-10-2012045.490.0012.50
2026Q4S2026-10-1912095.580.0012.50
2026Q4S2026-10-1412085.610.0012.50
2026Q4S2026-10-1311085.580.0012.50
2026Q4S2026-09-2810087.530.0025.00
2026Q4S2026-09-1511097.030.0025.00
2026Q4S2026-09-1010097.130.0025.00
2026Q4S2026-08-1411098.030.0025.00
2026Q4S2026-08-1111099.850.0045.00
2026Q4S2026-08-0611099.950.0045.00
2026Q4S2026-08-03110223.341.6548.00

Estimate history

EPS, annual-1.213-1.433-1.933-2.2430.714-3.708-4.149-3.141-3.287-3.6416
Period201720182019202020212022202320242025TTM
EPS, quarterly-1.007-1.025-1.1380-1.268-0.895-1.021-0.722-1.005
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual1.4138.3531577.517382.882112117258247100
Period201720182019202020212022202320242025TTM
Sales, quarterly482628160263317419
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual43.7544.53845.92565.11570.78272.975.592.2125.3127.6
Period201720182019202020212022202320242025MRQ
Shares, quarterly91.592.2105.9106.4107.1125.3125.5127127.6
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue100.00247.00258.00117.00112.00382.8877.5215.008.35
Cost of Goods Sold Incl. D&A9.0010.0010.0016.0014.007.06---
Gross Profit91.00237.00248.00101.0098.00375.82---
Selling, General and Administrative Excl. Other566.00623.00558.00441.00378.00321.58197.36100.1359.55
Research and Development473.00523.00448.00340.00288.00256.35159.3578.4849.65
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-475.00-386.00-310.00-340.00-280.0054.25-124.23-88.71-54.86
Interest Expense11.008.004.002.002.000.260.000.000.00
Unusual Expense0.000.0020.000.000.000.000.00--
Net Income Before Taxes-453.00-353.00-282.00-301.00-266.0054.65-122.86-84.71-49.59
Income Taxes0.000.001.006.001.001.810.000.000.00
Consolidated Net Income-453.00-353.00-283.00-307.00-267.0052.83-122.86-84.71-49.59
Net Income From Continuing Operations-453.00-353.00-283.00-307.00-267.0052.83-122.86-84.71-49.59
Net Income-453.00-353.00-283.00-307.00-267.0052.83-122.86-84.71-49.59
EPS (Recurring)-3.56-3.29-2.99-4.15-3.710.71-2.24-1.93-1.43
EPS (Basic, Before Extraordinaries)-3.64-3.29-3.14-4.15-3.710.76-2.24-1.93-1.43
EPS (Diluted)-3.64-3.29-3.14-4.15-3.710.71-2.24-1.93-1.43
EBITDA-466.00-376.00-300.00-324.00-266.0061.30-119.84-85.13-51.20
Non-Operating Income (Expense)33.0041.0052.0041.0016.000.661.384.005.26
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense65.0060.0060.0457.6751.3539.8121.828.983.87
Price To Earnings Ratio----22.3495.52---
Price To Sales Ratio32.9110.365.2012.0813.297.8218.3529.5144.64
Gross Margin91.0095.9596.1286.3287.5098.16---
Operating Margin-475.00-156.28-120.16-290.60-250.0014.17-160.27-591.39-656.76
Net Margin-453.00-142.91-109.69-262.39-238.3913.80-158.49-564.73-593.73
Shares Outstanding127.60125.3092.2075.5072.9070.7865.1145.9344.54
Market Capitalization2,688.312,688.311,362.611,429.741,497.392,843.001,685.41463.18478.77

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue9.0041.0017.0033.0026.00160.0028.0026.00
Cost of Goods Sold Incl. D&A2.002.002.003.002.002.003.003.00
Gross Profit7.0039.0015.0030.0024.00158.0025.0023.00
Selling, General and Administrative Excl. Other138.00135.00149.00144.00166.00166.00147.00126.00
Research and Development117.00113.00122.00121.00141.00139.00122.00101.00
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-131.00-96.00-134.00-114.00-142.00-8.00-122.00-103.00
Interest Expense3.003.003.002.003.002.001.002.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-128.00-91.00-128.00-106.00-135.000.00-112.00-93.00
Income Taxes0.000.000.000.000.000.000.001.00
Consolidated Net Income-128.00-91.00-128.00-106.00-135.000.00-112.00-94.00
Net Income From Continuing Operations-128.00-91.00-128.00-106.00-135.000.00-112.00-94.00
Net Income-128.00-91.00-128.00-106.00-135.000.00-112.00-94.00
EPS (Recurring)-1.00-0.72-1.02-0.89-1.270.00-1.14-1.03
EPS (Basic, Before Extraordinaries)-1.00-0.72-1.02-0.89-1.270.00-1.14-1.03
EPS (Diluted)-1.00-0.72-1.02-0.89-1.270.00-1.14-1.03
EBITDA-129.00-94.00-132.00-111.00-140.00-6.00-119.00-100.00
Non-Operating Income (Expense)6.008.009.0010.0010.0010.0011.0012.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense16.0015.0019.0015.0014.0015.0016.001.04
Price To Sales Ratio32.9133.2311.4811.436.043.315.485.29
Gross Margin77.7895.1288.2490.9192.3198.7589.2988.46
Operating Margin-1,455.56-234.15-788.24-345.45-546.15-5.00-435.71-396.15
Net Margin-1,422.22-221.95-752.94-321.21-519.230.00-400.00-361.54
Shares Outstanding127.60127.00125.50125.30107.10106.40105.9092.20
Market Capitalization2,688.313,877.582,707.542,948.461,447.46861.90830.851,362.61

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments981.00978.00759.001,009.00499.31728.65188.27256.54175.70
Short Term Receivables16.0025.0042.0043.00746.821.700.130.080.03
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets10.0013.0030.0014.0015.625.474.302.321.14
Total Current Assets1,007.001,016.00831.001,066.001,261.75735.82192.71258.95176.87
Net Property, Plant & Equipment98.00112.00143.00135.00137.4223.599.3311.1111.23
Total Investments and Advances32.0017.00110.00132.00185.006.640.204.590.89
Long-Term Note Receivable-0.006.002.00-----
Deferred Tax Assets425.00--------
Other Assets2.005.005.0010.007.736.250.870.281.50
Total Assets1,564.001,150.001,095.001,345.001,591.90772.29203.11274.93190.49
Short Term Debt Incl. Current Port. of LT Debt13.0012.0011.003.005.102.870.000.000.00
Accounts Payable42.0018.0017.0020.0010.2615.684.703.103.82
Income Tax Payable1.001.00-0.001.81----
Other Current Liabilities175.00195.00156.00170.00148.91103.1218.0013.838.91
Total Current Liabilities231.00226.00184.00193.00166.08121.6722.7116.9312.73
Long Term Debt185.00147.00110.00117.00116.8915.240.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities425.00--------
Other Liabilities92.00292.00339.00378.00467.48133.0816.5623.0523.89
Total Liabilities933.00665.00633.00688.00750.45269.9939.2739.9836.62
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00226.20
Common Equity631.00485.00462.00657.00841.45502.30163.84234.94-72.33
Total Shareholders Equity631.00485.00462.00657.00841.45502.30163.84234.94153.87
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity631.00485.00462.00657.00841.45502.30163.84234.94153.87
Total Liabilities & Stockholders Equity1,564.001,150.001,095.001,345.001,591.90772.29203.11274.93190.49
Book Value Per Share5.045.266.129.0111.897.713.575.28-1.65
Tangible Book Value Per Share5.045.266.129.0111.897.713.575.28-1.65
Full-Time Employees60162757750036623613910883
Price to Book Ratio6.652.412.752.143.403.372.832.041.94
Return on Assets-26.01-25.21-25.16-18.184.47-25.19-35.44-21.31-35.37
Return on Equity-63.26-59.77-54.87-35.647.86-36.89-42.48-25.51-41.91
Return on Invested Capital-43.26-44.78-53.67-34.505.51-23.74-51.70-21.11-34.50
Quick Ratio4.364.504.525.527.606.058.4915.2913.90
Current Ratio4.364.504.525.527.606.058.4915.2913.90

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-453.00-353.00-283.00-307.00-267.0052.83-122.86-84.71-49.59
Depreciation10.0010.0010.0016.0014.007.064.193.583.66
Other Funds (Non Cash)65.0055.0081.0056.0068.0059.5621.787.541.60
Funds from Operations-378.00-288.00-192.00-235.00-185.00119.45-96.89-73.59-44.33
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-87.00-194.0022.00-71.00623.00-375.62208.060.121.33
Cash from Operating Activities-465.00-482.00-170.00-306.00438.00-256.17111.17-73.46-43.00
Capital Expenditures-1.00-2.00-6.00-24.00-6.00-26.08-3.06-1.93-3.74
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments67.0068.00-78.00218.00-404.0022.21-431.3161.14-109.70
Purchase of Investments-860.00-1,076.00-1,043.00-788.00-1,241.00-718.87-739.66-247.75-261.55
Sale Or Maturity of Investments927.001,144.00965.001,006.00837.00741.08308.35308.89151.85
Other Uses0.000.000.000.00-6.000.000.000.000.00
Other Sources0.000.000.000.003.000.000.000.000.00
Cash from Investing Activities66.0066.00-84.00194.00-413.00-3.87-434.3759.21-113.44
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock312.00439.00237.0033.0023.00232.34438.681.12129.07
Repurchase of Common Pref Stock0.000.000.000.000.00-0.01-0.05-0.090.00
Sale of Common Pref Stock312.00439.00237.0033.0023.00232.35438.731.22129.07
Proceedsfrom Stock Options279.00429.00228.0025.000.00220.24433.780.00124.98
Issuance or Reduction of Debt, Net0.0049.0047.000.0010.005.000.000.000.00
Change in Long Term Debt0.0049.0047.000.000.000.000.000.000.00
Issuance of Long Term Debt0.0049.0047.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.00-7.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.00-7.000.000.000.000.000.000.00
Cash from Financing Activities312.00488.00277.0033.0033.00237.34438.681.12129.07
Net Change in Cash-87.0072.0023.00-79.0058.00-22.70115.48-13.13-27.36
Free Cash Flow-466.00-484.00-176.00-330.00432.00-282.25108.11-75.39-46.74
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow----3.45-13.16--
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments630.00702.00822.00981.00831.00911.00
Short Term Receivables23.0041.007.0016.0014.0020.00
Inventories0.000.000.000.000.000.00
Other Current Assets11.0013.0015.0010.0012.0015.00
Total Current Assets664.00756.00844.001,007.00857.00946.00
Net Property, Plant & Equipment33.0036.0038.0098.0042.0044.00
Total Investments and Advances67.0076.0057.0032.0013.0019.00
Deferred Tax Assets---425.00--
Other Assets54.0056.0058.002.0062.0066.00
Total Assets818.00924.00997.001,564.00974.001,075.00
Short Term Debt Incl. Current Port. of LT Debt14.0013.0013.0013.0013.0012.00
Accounts Payable44.0034.0039.0042.0042.0029.00
Income Tax Payable1.001.001.001.00--
Other Current Liabilities140.00150.00156.00175.00180.00169.00
Total Current Liabilities199.00198.00209.00231.00235.00210.00
Long Term Debt102.00101.00100.00185.0098.0097.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---425.00--
Other Liabilities159.00161.00164.0092.00205.00219.00
Total Liabilities460.00460.00473.00933.00538.00526.00
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity358.00464.00524.00631.00436.00549.00
Total Shareholders Equity358.00464.00524.00631.00436.00549.00
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity358.00464.00524.00631.00436.00549.00
Total Liabilities & Stockholders Equity818.00924.00997.001,564.00974.001,075.00
Book Value Per Share2.813.654.185.044.075.16
Tangible Book Value Per Share2.813.654.185.044.075.16
Full-Time Employees---601--
Price to Book Ratio6.657.384.295.852.641.62
Return on Assets-50.56-46.02-34.28-26.01-30.64-26.36
Return on Equity-114.11-90.82-69.95-63.26-68.13-50.34
Return on Invested Capital-27.83-16.11-20.51-12.99-25.280.00
Quick Ratio3.343.824.044.363.654.50
Current Ratio3.343.824.044.363.654.50

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-128.00-91.00-128.00-106.00-135.000.00
Depreciation2.003.002.003.002.002.00
Other Funds (Non Cash)17.0016.0019.0013.0015.0013.00
Funds from Operations-109.00-72.00-107.00-90.00-118.0015.00
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital21.00-47.00-31.00-30.0021.00-148.00
Cash from Operating Activities-88.00-119.00-138.00-120.00-97.00-133.00
Capital Expenditures0.000.000.00-1.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments82.0052.00114.00-181.0079.00137.00
Purchase of Investments-131.00-182.00-150.00-397.00-165.00-161.00
Sale Or Maturity of Investments213.00234.00264.00216.00244.00298.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities82.0052.00114.00-182.0079.00137.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock7.0016.003.00286.008.003.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock7.0016.003.00286.008.003.00
Proceedsfrom Stock Options0.000.000.00279.008.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.0049.00
Change in Long Term Debt0.000.000.000.000.0049.00
Issuance of Long Term Debt0.000.000.000.000.0049.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities7.0016.003.00286.008.0052.00
Net Change in Cash1.00-51.00-21.00-16.00-10.0056.00
Free Cash Flow-88.00-119.00-138.00-121.00-97.00-133.00

Revenue breakdown

License And Development Services2024: 222.00M 2025: 221.00M
Other Collaboration2024: 36.00M 2025: 26.00M
United States2024: 258.00M 2025: 247.00M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3013.63%13.2M96.7M1.80M
2026-10-1514.45%12.4M85.5M1.36M
2026-09-3015.43%13.1M85.0M1.32M
2026-09-1516.25%13.8M85.0M1.38M
2026-08-3115.39%13.1M85.0M1.29M
2026-08-1416.30%13.8M85.0M1.25M
2026-07-3115.51%13.1M84.6M1.22M
2026-07-1515.14%12.6M82.9M1.32M
2026-06-3015.26%12.6M82.9M1.31M
2026-06-1515.89%13.3M83.5M1.16M
2026-05-2914.00%11.7M83.6M1.19M
2026-05-1513.02%10.9M83.6M1.23M
2026-04-3013.11%10.9M83.0M1.23M
2026-04-1513.49%11.1M82.1M1.10M
2026-03-3112.03%9.9M82.1M1.25M
2026-03-1310.48%8.6M82.1M1.38M
2026-02-2711.28%9.3M82.1M1.54M
2026-02-1311.11%9.0M81.1M1.63M
2026-01-3010.10%8.2M81.2M1.85M
2026-01-1510.94%8.9M81.4M1.92M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.5014.0018.500.000.0000.000.000.994-0.0180.000
call5.0011.5016.000.0014.3560.000.000.990-0.0180.001
call7.509.0013.500.009.9280.000.000.986-0.0180.001
call10.006.5011.000.007.4040.000.000.980-0.0170.001
call12.504.008.500.005.1060.000.000.971-0.0170.002
call15.001.506.000.003.7420.000.000.833-0.0700.007
call17.500.105.005.303.9240.000.000.661-0.0860.011
call20.000.000.500.800.7206650.000.342-0.0500.011
call22.500.000.100.100.8102100.000.092-0.0210.005
call25.000.000.650.101.1711620.000.070-0.0260.004
call30.000.000.400.351.64272.000.000.052-0.0270.003
call35.000.005.000.151.8941.000.000.026-0.0190.002
call40.000.005.000.152.4521.000.000.039-0.0340.003
put2.500.000.050.006.0840.000.00-0.006-0.0160.001
put5.000.005.000.006.8020.000.00-0.039-0.0930.002
put7.500.005.000.002.9650.000.00-0.014-0.0170.001
put10.000.005.000.002.1070.000.00-0.020-0.0160.001
put12.500.000.050.052.52648.000.00-0.115-0.0790.006
put15.000.000.750.001.6930.000.00-0.167-0.0690.007
put17.500.000.500.452.9154170.00-0.351-0.1770.011
put20.000.002.951.401.87417.000.00-0.633-0.0600.011
put22.501.506.004.253.0031620.00-0.908-0.0200.005
put25.004.008.904.003.8683290.00-0.930-0.0230.004
put30.009.0013.508.204.3222720.00-0.948-0.0270.003
put35.0014.0018.900.005.3120.000.00-0.956-0.0290.003
put40.0019.0023.800.005.6020.000.00-0.961-0.0300.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-10-238-KCurrent report2026-10-21SEC
2026-10-22424B5SEC
2026-10-21424B5SEC
2026-10-218-KCurrent report2026-10-21SEC
2026-10-208-KCurrent report2026-10-20SEC
2026-09-28CT ORDERSEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-21144Filing for proposed sale of securities under Rule 144.SEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-07-134Statement of changes in beneficial ownership of securities2026-07-09SEC
2026-07-09144Filing for proposed sale of securities under Rule 144.SEC
2026-06-24144Filing for proposed sale of securities under Rule 144.SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-22SEC
2026-06-22144Filing for proposed sale of securities under Rule 144.SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-128-KCurrent report2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-01144Filing for proposed sale of securities under Rule 144.SEC
2026-06-014Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-05-124Statement of changes in beneficial ownership of securities2025-12-16SEC
2026-05-124Statement of changes in beneficial ownership of securities2026-05-11SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080084.81K1
2026-07002.03M2
2026-0600943.53K4
2026-0500198.97K1
2026-040000
2026-030000
2026-020000
2026-0100681.34K1
2025-12005.34M17
2025-11002.14M5

Institutional holders

Manager% owned
GILEAD SCIENCES, INC.24.68%
BlackRock, Inc.13.05%
STATE STREET CORP4.79%
WELLINGTON MANAGEMENT GROUP LLP4.69%
MONTANOVA CAPITAL, LLC3.80%
VANGUARD PORTFOLIO MANAGEMENT LLC3.56%
FMR LLC3.48%
VANGUARD CAPITAL MANAGEMENT LLC3.09%
CITADEL ADVISORS LLC2.49%
Woodline Partners LP2.39%

Funds

Fund% owned
iShares Core S&P Small-Cap ETF4.16%
VANGUARD HEALTH CARE FUND2.74%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.22%
State Street(R) SPDR(R) S&P(R) Biotech ETF2.06%
iShares Russell 2000 ETF1.83%
VANGUARD SMALL-CAP INDEX FUND0.80%
VANGUARD EXTENDED MARKET INDEX FUND0.80%
Fidelity Small Cap Index Fund0.78%
Select Biotechnology Portfolio0.67%
Fidelity Small Cap Growth Fund0.64%

OakChart. RCUS. Cached 15 minutes.